Data Presented From Study of Walk Vascular's Jeti Thrombectomy System

 

October 31, 2018—Walk Vascular, LLC announced data from a study assessing the safety and efficacy of the Jeti-8 peripheral thrombectomy system for the treatment of acute deep vein thrombosis.

According to the company, the Jeti system was tested in 23 venous thromboembolism cases with an 83% rate of technical success, defined as restoration of antegrade flow with the elimination of any obstructing lesion without overnight postprocedural lytic infusion via catheter-directed thrombolysis (CDT). However, four of the 23 procedures required postprocedure lytic infusion before achieving procedural and technical success with overnight CDT. No complications, hemolysis, or blood transfusion were reported. Mean thrombus removal across all patients was 93%, reported Walk Vascular.

The company describes the Jeti thrombectomy system as being designed to break-up and remove thrombus from the coronary and peripheral vasculature using a powerful internal jet technology that macerates thrombus just inside its mouth and lubricates the proximally flowing aspirate.

The study was presented by Jean Cournoyer-Rodrigue, MD, at CIRSE 2018, the Cardiovascular and Interventional Radiology Society of Europe annual meeting held September 22–25 in Lisbon, Portugal. Dr. Cournoyer-Rodrigue is from Centre Hospitalier de l'Université de Montréal Research Center in Montreal, Quebec.

 

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney
484-581-1816
cmcchesney@bmctoday.com

Stephen Hoerst
484-581-1817
shoerst@bmctoday.com

Charles Philip
484-581-1873
cphillip@bmctoday.com

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.